Physician profile
Allison Dawson
NPI 1114589256
$684.16
in general payments reported to CMS, 2019-2025
11 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $330 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $136.71 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $135.26 | 2024-2025 | Breztri, Tezspire, Farxiga |
| Glaxosmithkline, LLC. | $123.22 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $63.74 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $59.94 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $36.66 | 2024 | Inspire |
| Amgen INC. | $32.06 | 2025 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $30.30 | 2024 | |
| Abbvie INC. | $25.00 | 2023 | Vraylar |
| Novartis Pharmaceuticals Corporation | $20.96 | 2024 | |
| Novo Nordisk INC | $20.31 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.